Everything below concerns circular dichroism. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
=== Lobbying by competitors === According to The Washington Post, Meta hired the Republican consulting firm Targeted Victory to run a campaign aimed at turning public opinion against TikTok. Internal emails revealed that the firm sought to portray TikTok as "the real threat" and encouraged headlines such as "From dances to danger: how TikTok has become the most harmful social media space for kids." Operatives promoted stories to local media that tied TikTok to allegedly dangerous trends among teenagers, including the 2021 "devious lick" vandalism challenge, which evidence shows originated on Facebook. The campaign also sought to deflect attention from criticisms of Meta's own privacy and antitrust issues. A Meta spokesperson defended the effort, saying that all platforms, including TikTok, should face equal scrutiny. An analysis estimated that Meta, the parent company of Facebook and Instagram, could gain between $2.46 billion and $3.38 billion in advertising revenue if TikTok were banned. Reddit CEO Steve Huffman has publicly advocated for a ban on TikTok, calling the app "fundamentally parasitic" and a "spyware" in 2020.
=== Hypersensitivity === Hypersensitivity is a rarely described but significant complication of parenteral nutrition therapy. First reported in 1965, the incidence of these reactions is speculated to be around one in 1.5 million patients who are provided parenteral nutrition. There is a wide range in how and when these reactions manifest. Cutaneous manifestations are the most common presentation. Hypersensitivity is thought to occur to the individual components of TPN, with the intravenous lipid emulsion being the most frequently implicated component, followed by the multivitamin solution and the amino acid solution. Medications Patients who are receiving intravenous parenteral nutrition may also need to receive intravenous medications as well using the same Y-site. It is important to assess the compatibility of the medications with the nutrition components. Incompatibilities can be observed physically through discoloration, phase separation, or precipitation.
ACT-389949: A small-molecule FPR2 agonist that has completed phase 1 clinical trials BMS-986235: Another FPR2 agonist in phase 1 trials, with evidence of resolving cardiac inflammation and improving cardiac function in preclinical models. BLXA4 (Methyl ester-benzo-lipoxin A4): An LXA4 analog tested in phase 1 clinical trials for gingival inflammation, shown to reduce local inflammation. Rezuforimod is a potent and selective FPR2 agonist that inhibits neutrophil adhesion and exhibits broad anti-inflammatory activity.
Paralogous genes can shape the structure of whole genomes and thus explain genome evolution to a large extent. Examples include the Homeobox (Hox) genes in animals. These genes not only underwent gene duplications within chromosomes but also whole genome duplications. As a result, Hox genes in most vertebrates are clustered across multiple chromosomes with the HoxA-D clusters being the best studied. Another example are the globin genes which encode myoglobin and hemoglobin and are considered to be ancient paralogs. Similarly, the four known classes of hemoglobins (hemoglobin A, hemoglobin A2, hemoglobin B, and hemoglobin F) are paralogs of each other. While each of these proteins serves the same basic function of oxygen transport, they have already diverged slightly in function: fetal hemoglobin (hemoglobin F) has a higher affinity for oxygen than adult hemoglobin. Function is not always conserved, however. Human angiogenin diverged from ribonuclease, for example, and while the two paralogs remain similar in tertiary structure, their functions within the cell are now quite different. It is often asserted that orthologs are more functionally similar than paralogs of similar divergence, but several papers have challenged this notion. In collaborative work, Anton Yuryev and co-authors demonstrated that genome-wide protein–protein interaction networks contain a significantly higher frequency of self-interacting proteins (homodimers) and interactions between paralogous proteins than would be expected by chance.
== Further Information == ASTM E1588-10e1, Standard Guide for GSR analysis by Scanning Electron Microscopy/Energy Dispersive X-ray Spectrometry, American Society for Testing and Materials, West Conshohocken, PA, 2010. E. Boehm, Application of the SEM in forensic medicine, Scanning Electron Microscopy (1971) 553–560. M Christopher, J Warmenhoven, FS Romolo, M Donghi, R Webb, C Jeynes, NI Ward, A New Quantitative Method for Gunshot Residue Analysis by Ion Beam Analysis. Analyst, 2013, 138, 4649. O. Dalby, D. Butler, J.W. Birkett, Analysis of Gunshot Residue and Associated Materials—A Review, J. Forens. Sci. 55 (2010) 924–943. M. Grima, M. Butler, R. Hanson, A. Mohameden, Firework displays as sources of particles similar to gunshot residue, Science and Justice 52 (1) (2012) 49–57. H.H. Meng, B. Caddy, Gunshot residue analysis - review, J. Forens. Sci. 42 (1997) 553–570. P.V. Mosher, M.J. McVicar, E.D. Randall, E.H. Sild, Gunshot residue-similar particles produced by fireworks, Journal of the Canadian Society of Forens. Sci. 31 (3)(1998) 157–168. F.S. Romolo, M.E. Christopher, M. Donghi, L. Ripani, C. Jeynes, R.P. Webb, N.I. Ward, Integrated Ion Beam Analysis (IBA) in Gunshot Residue (GSR) characterisation. Forensic Sci. Int. 231 (2013), 219–228. F.S. Romolo. Advances in Analysis of Gunshot Residue. In Emerging Technologies for the analysis of forensic traces, Edited by Simona Francese, Springer Publishing Company, pagine 183–202, ISBN 978-3-030-20541-6. A.J. Schwoeble, D.L. Exline, Current Methods in Forensic Gunshot Residue Analysis, (2000) CRC Press LLC. J.S. Wallace, J.
Sources: en.wikipedia.org
=== Interfering chromogens === The nonspecificity of Jaffe's reaction causes falsely elevated creatinine results in the presence of protein, glucose, acetoacetate, ascorbic acid, guanidine, acetone, cephalosporins, aminoglycosides (mainly streptomycin), ketone bodies, α-keto acids, and other organic compounds. Ammonium is also an interferent; if the sample is plasma, care needs to be taken that ammonium heparin has not been used as an anticoagulant. Nonspecificity is markedly decreased in urine samples since urine creatinine levels are much higher than blood and it generally does not contain significant levels of interfering chromogens. The Jaffe reaction's nonspecificity remains an important issue. Diabetes patients are a high-risk population to develop chronic kidney disease (CKD) and, therefore, interferences from glucose and acetoacetate are of particular importance. Artifacts such as hemolysis, lipemia, and icteremia can also affect accuracy. Hemolysis releases Jaffe-reacting chromogens and therefore will falsely increase results. Lipemia and icteremia can inhibit optical readings and falsely decrease values. The procedure has been developed over time with the intention to minimize these interferents.
1993/1150) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation) Order 1993 (S.I. 1993/1151) Finance Act 1991 (Commencement and Transitional Provisions) Order 1993 (S.I. 1993/1152) Water Byelaws (Milngavie Waterworks, Loch Katrine, Loch Arklet, Glen Finglas) Extension Order 1993 (S.I. 1993/1153) Control of Pollution (Exemption of Certain Discharges from Control) (Scotland) Variation Order 1993 (S.I. 1993/1154) Control of Pollution (Registers) (Scotland) Regulations 1993 (S.I. 1993/1155) Control of Pollution (Discharges by Islands Councils) (Scotland) Regulations 1993 (S.I. 1993/1156) Robert Gordon University (Scotland) Order of Council 1993 (S.I. 1993/1157) Pneumoconiosis etc. (Workers' Compensation) (Payment of Claims) (Amendment) Regulations 1993 (S.I. 1993/1158) Social Security Revaluation of Earnings Factors Order 1993 (S.I. 1993/1159) Emulsifiers and Stabilisers in Food (Amendment) Regulations 1993 (S.I. 1993/1161) National Rivers Authority (Anglian Region) (Reconstitution of the Skegness District Internal Drainage Board) Order 1993 (S.I. 1993/1174) Reconstitution of the Denge and Southbrooks Internal Drainage Board Order 1993 (S.I. 1993/1175) Civil Aviation (Navigation Services Charges) (Third Amendment) Regulations 1993 (S.I. 1993/1176) Undersized Lobsters Order 1993 (S.I. 1993/1178) PARLIAMENT S.I. 1993/1181) Magistrates' Courts (Miscellaneous Amendments) Rules 1993 (S.I. 1993/1183) British Wool (Guaranteed Prices) (Revocation) Order 1993 (S.I. 1993/1184) Friendly Societies Act 1992 (Commencement No.
68Ga-Trivehexin is a radiotracer for positron emission tomography (PET), obtained by labeling the peptide conjugate Trivehexin (INN: relitegatide brexetan) with the positron emitting radionuclide gallium-68 (68Ga). 68Ga-Trivehexin targets (i.e., binds to) the cell surface receptor αvβ6-integrin and accumulates in αvβ6-integrin-abundant tissues after intravenous (i.v.) application. 68Ga-Trivehexin is thus applied for PET imaging of medical conditions associated with elevated αvβ6-integrin expression. αvβ6-Integrin, the biological target of 68Ga-Trivehexin, is a heterodimeric transmembrane cell adhesion receptor whose primary natural ligand is latency associated peptide (LAP) in its complex with transforming growth factor beta 1 (TGF-β1). Binding of αvβ6-integrin to LAP releases and thus, activates TGF-β1. In early-stage cancer, TGF-β1 acts as a tumor suppressor but can turn into a tumor promoter as cancers develop, and furthermore induces fibrosis, particularly of the lung. As the likely most important activator of TGF-β1, αvβ6-integrin is often found overexpressed in tumors and fibrosis, which is why 68Ga-Trivehexin PET imaging is primarily relevant in this medical context.
==== Antigen loading and release ==== Apart from CLIP-antigen exchange, HLA-DM also facilitates antigen-antigen exchange. It releases weakly bound peptides from the groove to load peptides with higher-affinity binding. This process occurs in endosomes once they have left the ER containing MHC and HLA-DM that have fused with antigen-containing lysosomes. Kinetic analysis studies have shown that HLA-DM loading occurs quickly and in many endosomes. Along the membrane of an endosome at the optimal acidity (pH=5.0), HLA-DM loads 3 to 12 peptides onto different MHC molecules per minute. HLA-DM assists in catalysis of peptide exchange not only in late endosomes traveling from the ER, but also on cell membranes and in early endosomes. Much of this pathway is still being researched, but it is known that HLA-DM can load exogenous peptides onto MHC class II molecules when they are being expressed on cell surfaces. Loading can also occur in early endosomes that are quickly recycled. In both of these areas, loading occurs slower due to an altered pH environment. Release To release peptides from the MHC groove, HLA-DM binds to the N terminus of the groove, altering its conformation and breaking hydrogen bonds such that the peptide that was interacting with the MHC groove can no longer bind and is ejected. Loading Quick loading of peptides, facilitated by a stable MHC-DM complex, decreases the chances of those peptides being broken down by the proteolytic environment in the endosome. HLA-DM dissociates from the MHC once a stable enough peptide has bound.
Other invertebrates may have no rigid structures but the epidermis may secrete a variety of surface coatings such as the pinacoderm of sponges, the gelatinous cuticle of cnidarians (polyps, sea anemones, jellyfish) and the collagenous cuticle of annelids. The outer epithelial layer may include cells of several types including sensory cells, gland cells and stinging cells. There may also be protrusions such as microvilli, cilia, bristles, spines and tubercles. Marcello Malpighi, the father of microscopical anatomy, discovered that plants had tubules similar to those he saw in insects like the silk worm. He observed that when a ring-like portion of bark was removed on a trunk a swelling occurred in the tissues above the ring, and he unmistakably interpreted this as growth stimulated by food coming down from the leaves, and being captured above the ring.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.